Stryker Corporation (SYK)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$303.13-1.58%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Stryker grows sales about 8.75% a year as it expands its trauma and orthopedic products. Profit per share stays near $15 in 2026. New products and acquisitions support steady growth. The company manages cybersecurity risks and keeps costs controlled.
Sales growth slows below 8%. Profit per share falls below $14.90. Cybersecurity issues or litigation disrupt operations. New product launches fail to gain traction.
The current price reflects about 11% revenue growth and EPS near $15 for 2026. Our view aligns with these expectations but sees risk if growth or profit weakens.
Breaks if: Adjusted EPS falls below $14.90 in FY26
Stryker aims to maintain adjusted EPS guidance in the range of $14.90 to $15.10 for 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder in the healthcare sector. The current thesis is stable, supported by strong recent financial performance and management's commitment to growth.
The market appears to have priced in a low level of fragility, reflecting weak execution quality but not an overly expensive valuation. SYK is viewed as cheap compared to its peers, with a slight expectations gap.
Management is on track to maintain strong organic net sales growth and adjusted EPS growth, despite past challenges like a cybersecurity incident. The near-term risk of missing earnings remains low, although the company has experienced misses in recent quarters.
Key factors to watch include guidance updates from management and performance of sector bellwethers like ABT, MDT, and BSX. Additionally, any signs of economic weakness, such as a declining jobs report, could negatively impact SYK.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis of strong organic net sales growth. However, supply chain disruptions may hinder that same growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Material operational disruption or new cybersecurity incidents occur
Stryker is focused on addressing the cybersecurity incident that affected its IT systems.
Breaks if: YoY revenue growth falls below 8.0% in FY26
Overall, SYK's fundamentals are solid, but the investment thesis will depend on management's execution and broader sector trends. Not investment advice.